drugset / Trial / NCT05481827
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Phase 2
Enrolling by invitation
225 enrolled
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.
Timeline
- Start
- 2022-07-12
- Primary completion
- 2028-06-02
- Completion
- 2028-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT005 | Gene therapy (AAV / viral vector) | — | — |